Optimality Considerations in Two‐Stage Biomarker‐Stratified Trials With Adaptive Enrichment
Statistics in Medicine · 2025
DOI: 10.1002/sim.70318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Lang Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Biomarkers, Clinical Trials as Topic, Randomized Controlled Trials as Topic. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
We consider biomarker‐stratified trials that test the treatment effect in a targeted patient group, the biomarker positive subgroup, and in the overall population. If the biomarker negative subgroup is stopped for futility during the interim analysis the number of participants assigned can be increased. Optimal two‐stage designs are obtained using several optimality criteria. Recommendations are given on the best interim analysis timing, futility boundaries, α allocation between the two hypotheses and stage 2 sample size for the biomarker positive subgroup in case its complement, the biomarker negative subgroup, is stopped for futility in the interim analysis. This work is motivated by PrecISE, a two‐stage biomarker‐stratified clinical trial in patients with severe asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Lang Li
Zitieren
APA
Li, L., & Ivanova, A. (2025). Optimality Considerations in Two‐Stage Biomarker‐Stratified Trials With Adaptive Enrichment. Statistics in Medicine. https://doi.org/10.1002/sim.70318
Vancouver
Li L, Ivanova A. Optimality Considerations in Two‐Stage Biomarker‐Stratified Trials With Adaptive Enrichment. Statistics in Medicine. 2025. doi:10.1002/sim.70318
BibTeX
@article{Li2025,
author = {Li, Lang and Ivanova, Anastasia},
title = {Optimality Considerations in Two‐Stage Biomarker‐Stratified Trials With Adaptive Enrichment},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70318}
}
EUVIMED